Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 May 25;804(2):289-94. doi: 10.1016/j.jchromb.2004.01.023.

Abstract

A rapid method was developed for the quantitative determination of the novel histone deacetylase inhibitor, MS-275, in human plasma. Calibration curves were constructed in the range of 1-100 ng/ml, and were analyzed using a weight factor proportional to the nominal concentration. Sample pretreatment involved a one-step protein precipitation with acetonitrile of 0.1 ml samples. The analysis was performed on a column (75 mm x 4.6 mm i.d.) packed with 3.5 microm Phenyl-SB material, using methanol-10mM ammonium formate (55:45 (v/v)) as the mobile phase. The column effluent was monitored by mass spectrometry with positive electrospray ionization. The values for precision and accuracy were always < or =5.58 and <11.4% relative error, respectively. The method was successfully applied to examine the pharmacokinetics of MS-275 in a cancer patient.

MeSH terms

  • Administration, Oral
  • Benzamides / administration & dosage
  • Benzamides / blood*
  • Benzamides / pharmacokinetics
  • Chromatography, Liquid / methods*
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / blood*
  • Enzyme Inhibitors / pharmacokinetics
  • Histone Deacetylase Inhibitors*
  • Humans
  • Pyridines / administration & dosage
  • Pyridines / blood*
  • Pyridines / pharmacokinetics
  • Reproducibility of Results
  • Spectrometry, Mass, Electrospray Ionization / methods*

Substances

  • Benzamides
  • Enzyme Inhibitors
  • Histone Deacetylase Inhibitors
  • Pyridines
  • entinostat